Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
Not intended for US and UK audiences BI 765423 has been developed…
JASCAYD (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China
The approval marks the first new treatment option for people living with…


